Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00953290
Other study ID # CTCS002
Secondary ID
Status Terminated
Phase N/A
First received August 4, 2009
Last updated May 6, 2011
Start date January 2009
Est. completion date January 2010

Study information

Verified date May 2011
Source Cutera Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the Cutera radio frequency (RF) device for the new indication of reduction of thigh circumference.


Description:

The purpose of this study is to evaluate the Cutera radio frequency device for the new indication of reduction of thigh circumference.

At investigator's discretion, each subject will receive up to three treatments on one thigh and will be scheduled for two follow-up visits after the final treatment. The treated thigh will be clinically evaluated for side effects and both treated and untreated control thigh will be measured and photographed at each visit for analysis. Subjects will also be weighted at each visit and asked to fill out a survey during follow-up visits.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Body Mass Index between 20 and 35

- Presence of cellulite grades II, III or IV according to GLD scale

- Visible bi-lateral thigh fat Thigh area to be treated to measure at least 30.0mm in vertical fold, as measured with industry standard fat caliper

- Subject must be able to read, understand and sign the Consent Form

- Subject must adhere to the follow-up schedule and study instructions

- Subject must adhere to the same diet and/or exercise routine throughout the study

Exclusion Criteria:

- Significant weight fluctuation (+/-10 lbs) in the past 6 months

- Taking weight-loss medications/supplements

- Participation in any other clinical study

- Cellulite treatment within 3 months of the treatment

- Surgical or non-surgical treatments to the target area in the last 12 months, e.g., liposuction

- Prior treatment to the target area within the last 12 months

- Arteriosclerosis or weakened blood vessels

- Heart disease

- Thromboembolic disease

- Diagnosed or documented immune system disorders

- Bleeding disorders.

- Presence of uncontrolled hypertension

- Taking prescription anticoagulants

- History of keloid formation

- Malignant tumors in the target area

- Diabetes

- Any disease or condition that could impair wound healing

- Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars

- Infection in the target area

- Implanted electrical device(s)

- Pregnant or lactating

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Reduction of Localized Excess Fat

Intervention

Device:
Cutera Radio Frequency Device
Up to three treatments, one pass, dosage range of 15-60 kJ.

Locations

Country Name City State
United States Blackhawk Plastic Surgery Danville California

Sponsors (1)

Lead Sponsor Collaborator
Cutera Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in Circumference of Upper Thigh Between Treated and Untreated Control Arms Mean difference of change from baseline between two arms: [Treated arm - Untreated arm] Baseline and 6 months post final treatment No
Primary Difference in Circumference of Mid Thigh Between Treated and Untreated Control Arms Mean difference of change from baseline between two arms: [Treated arm - Untreated arm] Baseline and 6 months post final treatment No
Secondary Subject Satisfaction Baseline and 6 months post final treatment No
Secondary Adverse Events At each visit (treatment and follow-up) or until resolution of AEs Yes